Abstract
Pulmonary surfactant is a complex mixture of lipoproteins synthesized, secreted and recycled by type Ⅱ alveolar cells.The primary function of PS is to minimize the surface tension at the alveolar air-liquid interface.Surfactant dysfunction with quantitative and qualitative abnormalities of both phospholipids and proteins are characteristics of patients with acute respiratory distress syndrome (ARDS). Exogenous surfactant replacement shows consistent improvements in gas exchange, but had limited success in improving survival.These may be due to variety of aetiologies in ARDS、surfactant compositiones, delivery methods, optimal time and doses.At this time, surfactant therapy cannot be recommended as routine therapy in pediatric ARDS. Key words: Pulmonary surfactant; Children; Acute respiratory distress syndrome
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
